Abstract:: Surgical resection has been the mainstay for the treatment of thymic malignancies, probably because most of these tumors are relatively indolent in nature. Even if complete resection could not be accomplished, volume reduction surgery such as tumor debulking together with adjuvant radiation to the residual lesion may still be associated with prolonged survival of the patients. Therefore, upfront surgery has long been a common practice in the management of thymic tumors. Even so, incomplete resection would without doubt lead to dismal prognosis, like in most solid tumors. In the Chinese Alliance for Research in Thymomas (ChART) database study, radical resection rate was only 72.6% in Masaoka stage III diseases as opposed to 99.7% in stage I and 95.4% in stage II tumors. It is thus not surprising that 10-year overall survival was merely 64.8% in stage III patients, while in stage I and II they were as high as 94.3% and 89.8%, respectively. And complete resection, together with Masaoka staging and WHO histology subtype, turned out to be the three main prognostic factors for thymic tumors. It is understandable to sort to adjuvant therapies in hope of improving the unsatisfactory outcomes after upfront surgery in stage III thymic tumors. Unfortunately the two ChART multi-center cohort studies on post-operative chemotherapy and radiotherapy failed show any benefit from adjuvant therapy in locally advanced diseases after surgery. Although adjuvant radiation is still recommended by current guidelines, it should be bear in mind that these suggestions are based on low-level evidences and that there has never been any strictly designed studies to prove its efficacy. A reasonable solution would be shifting from post-operative adjuvant treatment to neoadjuvant therapies before surgery, with the hope that effective induction could downstage the tumor and increase the chance of complete resection. According to the ChART retrospective database, although only a small percentage of patients (12.1% in stage III & IV tumors) received induction therapies, 25% of them had their tumors downstaged, leading to 93.8% survival rate in this subgroup. But up till now, standard induction approaches have not yet been established, probably due to the rarity of the disease. A previous retrospective study comparing different treatment modalities for inoperable thymic tumors at the Shanghai Chest Hospital has shown that concurrent chemoradiation had the highest response rate (87.5%) and thus the best 5-year survival (61.9%) comparing to sequential chemoradiation or radiation alone. Based on these results, a phase II trial on neoadjuvant chemoradiation (two cycles of cisplatin and paclitaxel chemotherapy together with 36–40 Gy IMRT) for potentially unresectable thymic tumors yield satisfactory results. Overall response rate was as high as 79%, with 58% of the lesions downstaged after induction. Complete resection was achieved in 85.7% cases, with a 33% complete response rate upon histological examination. A 65.8% survival rate was achieved in these patients with originally unresectable tumors. On the other hand, Masaoka stage III is a heterogeneous group of tumors ranging from readily resectable diseases (equals to IASLC/ITMIG T2–3, such as limited invasion into the pericardium or lung), to basically unresectable lesions (IASLC/ITMIG T4, invading into the heart or great vessels such as the pulmonary artery and aorta). While minimally invasive surgery has been increasingly used in the management of early stage thymic tumors, its role in locally advanced diseases has yet to be investigated. After the ChART has recently proved the oncological efficacy of minimally invasive thymectomy for IASLC/ITMIG stage I tumors through a multi-center cohort study, similar results was found in stage II and III tumors through a propensity score matching analysis in patients treated at the Shanghai Chest Hospital. Complete resection rate turned out to be similar in both minimally invasive and open surgery groups, with comparable survival and recurrence rates. This suggests that the benefit of minimally invasive surgery may still be expected in well selected group of patients with invasive tumors. So for locally advanced thymic malignancies, the IASLC/ITMIG staging system is more useful in differentiating those resectable or unresectable diseases and help selecting candidates for upfront surgery. And for those potentially unresectable tumors, effective induction (especially concurrent chemoradiation) may offer the best chance for tumor downstaging and hitherto improved outcome.

Neoadjuvant Chemotherapy and Operation for Invasive Masaoke Stage III and IVa Thymoma

NEOADJUVANT CHEMOTHERAPY AND OPERATION FOR INVASIVE MASAOKE STAGE Ⅲ AND Ⅳa THYMOMA

Surgical Treatment of Invasive Thymoma: a Prognostic Retrospective Study

Surgical resection after neoadjuvant concurrent chemoradiotherapy for stage Ⅲ invasive thymic tumor: A phase Ⅱ prospective clinical trial

Neoadjuvant radiotherapy plus single-incision thoracoscopic surgery in the treatment of type B3 thymomas

Treatment and Prognosis of Masaoka Stage 3 Thymic Carcinoma: a Retrospective Study of 32 Cases

The Application of Postoperative Chemotherapy in Thymic Tumors and Its Prognostic Effect.

Clinical Value of Chemotherapy for Thymictumors: a Retrospective Analysis Based on the Results of the Chinese Alliance of Research for Thymomas Database

Bilateral Video-Assisted Thoracoscopic Thymectomy for Masaoka Stage IIIA Thymomas.

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Role of Adjuvant Radiotherapy for Stage Ii Thymoma after Complete Tumor Resection

Analysis of treatment and prognosis of 73 thymic carcinoma patients

Surgery in Masaoka Stage IV Thymic Carcinoma: a Propensity-Matched Study Based on the SEER Database.

AB010. Management of Locally Advanced Thymic Malignancies

Surgical Therapy for Thymomas or Thymoma-Associated Myasthenia Gravis

Multimodal management of stages III–IVa malignant thymoma

Diagnosis and surgical treatment of 135 cases of thymoma

Single-center evaluation of prognostic factors for thymoma treated by surgery: a retrospective study

Surgical Approach for Stage Ⅳ A Thymoma-a Clinical Experience with 7 Cases

Pathological Features and Surgical Effect of Invasive Thymoma

Invasion Characteristics and Validation of the T Descriptor in the 8th Edition of TNM Staging System for Patients with Masaoka-Koga Stage III Thymoma